Sedana Medical AB (SEDANA) fair value: what the stock is really worth
As of Sep 28, 2026: fair value of Sedana Medical AB SEK 1.21, price SEK 9.85, upside -87.7%, quality 41 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Sedana Medical AB for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 28, 2026.
How to read this chart
60‑month range kr 6.88 – kr 107.10 · fair‑value band kr 0.8000 – kr 1.51 · the kr 9.85 price screens above the kr 1.21 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 28, 2026.
Follow Sedana Medical in your weekly email
Every Wednesday you see whether Sedana Medical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Sedana Medical AB (publ), a medtech and pharmaceutical company, develops, manufactures, and sells medical devices and pharmaceutical products in Sweden, Spain, Germany, and internationally.
Show more
Sedana Medical AB (publ), a medtech and pharmaceutical company, develops, manufactures, and sells medical devices and pharmaceutical products in Sweden, Spain, Germany, and internationally. The company offers Sedaconda ACD-L and Sedaconda ACD-S, which are disposable medical devices that enable the administration of volatile anaesthetics; Sedaconda Syringe, a syringe with a connection to fit the connector on the agent line of the Sedaconda ACD and Sedana Medical filling adapters; Sedaconda ACD starter kit; Sedaconda (Isoflurane) for maintenance of sedation in intubated or tracheostomised mechanically ventilated adult and paediatric patients from 3 years of age; Sedaconda Filling Adapter, a single-use medical device; FlurAbsorb Pro-L and Pro-S; FlurAbsorb and Mounts; Scavenging Tube, a one piece pre-connected tube, that is designed to channel anaesthetic waste gas from the ventilator exhaust port and the gas monitor exhaust port to the FlurAbsorb filter; and Mindray exhaust connector enables to connect the exhaust of the ventilator to an active or passive scavenging system. The company was founded in 1999 and is headquartered in Danderyd, Sweden.
Stock analysis
Sedana Medical AB (SEDANA) currently trades at kr 9.85, while our model-based Fair Value estimate is kr 1.21, implying the stock looks roughly 714.3% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: kr 0.8000 (bear) to kr 1.51 (bull), the price of kr 9.85 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Sedana Medical AB reported revenue of 200M SEK in FY2025 versus 159M SEK in FY2021, a compound +5.9%/yr. Reported net income was −59.2M SEK in FY2025.
Key figures
Market cap 978M SEK (≈ $98.2M) · P/S ratio 4.46 · EPS (TTM) kr −0.4000 · Net margin −29.6% · Return on equity −4.3% · Return on assets (EBIT) −5.9% · Operating margin −9.9% · Revenue (TTM) 196M SEK.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 28% below its 52-week high and 24% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −88%, SEDANA screens richer than that median.
Fair Value models
Bear kr 0.8000Fair Value kr 1.21Bull kr 1.51
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.22/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+12.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.1%
Start year 2020 (pandemic). Over 10 years: +21.7% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.7%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−15.2% (2020) → −16.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 360 stocks
Beats the industry median on 2/8 measures
Overall it trails its industry peers.
Valuation
Quality Score43 · Below median
Fair Value upside−87.7% · Bottom 25%
Profitability
Return on assets−2.1% · Below median
Net margin (TTM)−20.2% · Bottom 25%
Operating margin (TTM)−9.9% · Below median
Growth and dividend
Revenue growth−7.1% · Bottom 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/B0.11× · Cheapest 25%
P/S (TTM)0.50× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 11
FUTURE (revenue growth)0· sector 31
PAST (return on equity)0· sector 5
HEALTH (low debt)100· sector 97
DIVIDEND (yield)0· sector 38
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Sedana Medical AB Fair Value". https://www.fairvalue-calculator.com/stock/SEDANA
Frequently asked questions
Is Sedana Medical AB (SEDANA) overvalued or undervalued?
As of Sep 28, 2026, our model estimates a fair value of kr 1.21 versus a price of kr 9.85, about −88% upside (overvalued).
What is the fair value of SEDANA?
Our model-based fair value for Sedana Medical AB is kr 1.21 (as of Sep 28, 2026), built from audited fundamentals. The current price: kr 9.85.
What is the quality score of SEDANA?
Sedana Medical AB has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sedana Medical AB (SEDANA)?
Our model-based price target is the fair value of kr 1.21 (as of Sep 28, 2026) from 1 valuation models. Cautious scenario kr 0.8000, optimistic scenario kr 1.51. It is a calculation from audited fundamentals, not an analyst target.
What is the Sedana Medical AB stock forecast for 2026?
Our models put fair value at kr 1.21, about −88% upside versus a price of kr 9.85 (overvalued). Cautious scenario kr 0.8000, optimistic scenario kr 1.51. The calculation is refreshed regularly with new filings.
What is the revenue of Sedana Medical AB (SEDANA)?
Sedana Medical AB reported trailing-twelve-month revenue of about 196M SEK (latest available figure, as of Sep 28, 2026).
What is the intrinsic value of Sedana Medical AB (SEDANA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sedana Medical AB it is kr 1.21 per share (as of Sep 28, 2026), against a price of kr 9.85. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Sedana Medical AB stock overvalued or undervalued in 2026?
As of Sep 28, 2026, SEDANA trades above its calculated fair value: price kr 9.85, fair value kr 1.21, a gap of about −88% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SEDANA?
No. The price is what the market pays today (kr 9.85); the fair value is what the company's own numbers justify (kr 1.21). For Sedana Medical AB the two are kr 8.64 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sedana Medical AB worth?
The market values Sedana Medical AB at about 978M SEK (market capitalisation, as of Sep 28, 2026). Per share that is kr 9.85; our models calculate a fair value of kr 1.21 per share.
What do the bullish and bearish scenarios say about SEDANA?
Our models span a range for Sedana Medical AB: cautious scenario kr 0.8000, base kr 1.21, optimistic kr 1.51 per share (as of Sep 28, 2026, price kr 9.85). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Sedana Medical AB (SEDANA)?
Balance-sheet figures for Sedana Medical AB (as of Sep 28, 2026): return on equity −4.3%. They feed the Quality Score of 41/100, which measures business quality independently of the share price.
How far is SEDANA from its 52-week high?
Sedana Medical AB trades at kr 9.85, about 28% below its 52-week high of kr 13.62 and 24% above the low of kr 7.93 (as of Sep 28, 2026). Distance from the high says nothing about value: that is what the fair value of kr 1.21 is for.
Which stocks are comparable to Sedana Medical AB?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sedana Medical AB stock attractive at the current price?
The data as of Sep 28, 2026: price kr 9.85, calculated fair value kr 1.21 (−88%), Quality Score 41/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SEDANA calculated?
We run Sedana Medical AB through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 1.21, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.9 % above its aggregate fair value. Sedana Medical AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sedana Medical AB (SEDANA)?
The closing price on Sep 28, 2026 was kr 9.85. Our model-based fair value is kr 1.21, about −88% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sedana Medical AB right now?
The price sits above even our optimistic bull case (kr 1.51). The favourable scenario is already priced in. Weak quality (41/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (kr 0.8000 to kr 1.51) leaves room in how you read the outcome.
Key figures of Sedana Medical AB
How large is the market capitalisation of Sedana Medical AB (SEDANA)?
The market capitalisation of Sedana Medical AB is 978M SEK (≈ $98.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sedana Medical AB (SEDANA)?
The price-to-sales ratio of Sedana Medical AB is 4.46 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Sedana Medical AB (SEDANA)?
Earnings per share at Sedana Medical AB are kr −0.4000. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Sedana Medical AB (SEDANA)?
The net margin of Sedana Medical AB is −29.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sedana Medical AB (SEDANA)?
The return on equity (ROE) of Sedana Medical AB is −4.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sedana Medical AB (SEDANA)?
On an EBIT basis the return on assets of Sedana Medical AB is −5.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sedana Medical AB (SEDANA)?
The operating margin of Sedana Medical AB is −9.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sedana Medical AB (SEDANA)?
Revenue at Sedana Medical AB is growing −7.1% versus a year earlier (3y avg +17.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Sedana Medical AB (SEDANA) generate?
The free cash flow of Sedana Medical AB is −75.2M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Sedana Medical AB (SEDANA) hold?
Sedana Medical AB holds more cash than debt, 86.3M SEK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Sedana Medical AB in the live analysis
One click puts Sedana Medical AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
